Aratana Therapeutics to Attend North American Veterinary Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Aratana Therapeutics (PETX) Shares Decline Following Update on ENTYCE Availability
February 6, 2017 10:59 AM ESTAratana Therapeutics (NASDAQ: PETX) declined Monday after saying in an SEC filing that ENTYCE (capromorelin oral solution) won't be commercially available until late-2017.
From the filing:
In connection with the 2017 North American Veterinary Conference in Orlando, Florida, on February 6, 2017, Aratana Therapeutics, Inc. (the Company) provided certain business updates.
The Company now anticipates that ENTYCE® (capromorelin oral solution) will... More